Pipeline Highlights

Our product pipeline reflects our commitment to developing innovative products that can help improve people’s lives. This page features information on many of the compounds currently in our pipeline, including those we expect to launch soon. Information on this page is current as of November 6, 2018.

Late Phase/Future Catalysts 3 

  • New Material (Ophthalmic Viscosurgical Device); First Patient In: May 9, 2018
  • Loteprednol Gel 0.38% (ocular inflammation); PDUFA date – February 25, 2019
  • enVista® Trifocal (Intraocular Lens) – First Patient In: May 24, 2018
  • OHE Study: Phase 2 study with a new formulation of rifaxamin is ongoing 
  • SIBO Study: Activities underway for commencing in 1H19
  • Agreed to expand license terms for three additional budesonide programs from Dr. Falk Pharma 
  • Expanded microbiome research and discovery through strategic collaboration with Cedars-Sinai Medical Center
  • Expected to initiate late-stage clinical program with Alfasigma S.p.A. to study investigational formulation of rifaximin in patients with post-operative Crohn’s disease
  • DUOBRII™1 (IDP-118 Psoriasis) – PDUFA Feb. 15, 2019
  • IDP-120 (acne) Phase 3 expected to begin Nov. 2018
  • IDP-123 (acne) Phase 3 studies completed; NDA expected to be submitted 1H19
  • IDP-124 (atopic dermatitis) Initiated Phase 3 in 2Q18
  • IDP-126 (acne combination) Phase 2 topline results expected – 1H2019


Launches

  • Vitesse® vitreous cutter – 4Q17 Launch 2
  • VYZULTA® – 4Q17 Launch
  • Bausch + Lomb ULTRA® contact lenses extended wear indication – Approved May 2018
  • PreserVision® AREDS 2 Formula Chewable – May 2018 Launch
  • LUMIFY® – May 2018 Launch
  • Ocuvite® Blue Light Eye Vitamins – June 2018 Launch
  • Soothe® XP Preservative Free Eye Drops – June 2018 Launch
  • enVista® Toric IOL –  Approved June 8, 2018, first U.S. commercial implant in July 2018
  • AQUALOX™ (SiHy Daily) –  Sept. 2018 launch in Japan; Plans for global rollout 
  • LUCEMYRA™ US WorldMeds Co-Promotion – August 2018 Launch
  • PLENVU® (NER1006) – September 2018 Launch
  • DOPTELET® Dova Pharmaceuticals Co-Promotion - October 2018 Start
  • SILIQ™ – 3Q17 launch 
  • Thermage FLX™ System – 4Q17 Launch 2
  • RETIN-A MICRO® 0.06% - 1Q18 Launch
  • ALTRENO™ (IDP-121 Acne Lotion) – Oct. 2018 Launch
  • BRYHALI™ (IDP-122 Psoriasis) –Approved Nov. 6, 2018

1. Provisional name.
2. Limited launch.
3. Subject to FDA approval.

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
Copyright © 2018 Bausch Health. All rights reserved.